Research analysts at StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the stock.
Ampio Pharmaceuticals Stock Performance
Shares of AMPE stock opened at $2.60 on Monday. Ampio Pharmaceuticals has a fifty-two week low of $2.35 and a fifty-two week high of $13.20. The firm has a market cap of $2.16 million, a P/E ratio of -0.21 and a beta of 1.84. The business’s 50 day moving average price is $3.17 and its 200-day moving average price is $4.23.
Ampio Pharmaceuticals (NYSE:AMPE – Get Free Report) last released its quarterly earnings results on Tuesday, November 14th. The company reported ($1.53) earnings per share for the quarter.
Institutional Investors Weigh In On Ampio Pharmaceuticals
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. HRT Financial LP increased its stake in shares of Ampio Pharmaceuticals by 1,399.2% during the first quarter. HRT Financial LP now owns 217,052 shares of the company’s stock valued at $50,000 after purchasing an additional 202,574 shares in the last quarter. Two Sigma Advisers LP increased its position in Ampio Pharmaceuticals by 304.3% during the 3rd quarter. Two Sigma Advisers LP now owns 432,216 shares of the company’s stock valued at $26,000 after buying an additional 325,300 shares in the last quarter. Vanguard Group Inc. raised its stake in Ampio Pharmaceuticals by 20.0% during the third quarter. Vanguard Group Inc. now owns 9,954,092 shares of the company’s stock valued at $602,000 after buying an additional 1,662,127 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Ampio Pharmaceuticals by 73.5% in the second quarter. Price T Rowe Associates Inc. MD now owns 394,100 shares of the company’s stock worth $66,000 after acquiring an additional 166,979 shares in the last quarter. Finally, Millennium Management LLC grew its stake in shares of Ampio Pharmaceuticals by 998.6% in the second quarter. Millennium Management LLC now owns 2,035,413 shares of the company’s stock worth $342,000 after acquiring an additional 1,850,138 shares during the last quarter. 3.10% of the stock is owned by hedge funds and other institutional investors.
About Ampio Pharmaceuticals
(Get Free Report)
Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis-related pain. It focuses on the preclinical development of AR-300, a novel proprietary, small molecule formulation for the treatment of osteoarthritis of the knee. The company is headquartered in Englewood, Colorado.
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.